Data as of Apr 17
| -0.48 / -0.60%|
The 9 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 110.00, with a high estimate of 144.00 and a low estimate of 62.00. The median estimate represents a +39.42% increase from the last price of 78.90.
The current consensus among 10 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.